Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial

Open access

Abstract

It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporter blockade, altered dopamine signaling and psychological factors may contribute. In this randomized clinical trial of participants with social anxiety disorder (SAD) we investigated how manipulation of verbally-induced expectancies, vital for placebo response, affect brain monoamine transporters and symptom improvement during SSRI treatment. Twenty-seven participants with SAD (17 men, 10 women), were randomized, to 9 weeks of overt or covert treatment with escitalopram 20 mg. The overt group received correct treatment information whereas the covert group was treated deceptively with escitalopram, described as an active placebo in a cover story. Before and after treatment, patients underwent positron emission tomography (PET) assessments with the [11 C]DASB and [11 C]PE2I radiotracers, probing brain serotonin (SERT) and dopamine (DAT) transporters. SAD symptoms were measured by the Liebowitz Social Anxiety Scale. Overt was superior to covert SSRI treatment, resulting in almost a fourfold higher rate of responders. PET results showed that SERT occupancy after treatment was unrelated to anxiety reduction and equally high in both groups. In contrast, DAT binding decreased in the right putamen, pallidum, and the left thalamus with overt SSRI treatment, and increased with covert treatment, resulting in significant group differences. DAT binding potential changes in these regions correlated negatively with symptom improvement. Findings support that the anxiolytic effects of SSRIs involve psychological factors contingent on dopaminergic neurotransmission while serotonin transporter blockade alone is insufficient for clinical response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-021-01682-3

Cites

Statistics

Figures

Fig. 1 Study design and main results. A Shows the whole-sample distribution of serotonin (SERT) and dopamine (DAT) transporters, expressed as non-displacable binding potentials (BPND) at the baseline PET assessment. B Illustrates the experimental manipulation; high or low response expectancies were induced by different verbal instructions. All patients were then treated under randomized conditions with escitalopram 20 mg for 9 weeks, correctly described as an effective SSRI for the overt group and incorrectly described as an active placebo in the covert group. C Shows the treatment effects on PET measures. Overt as compared to covert SSRI treatment resulted in lowered DAT availability, the significant cluster in the right putamen/pallidum is shown together with percent BPND change from pre- to posttreatment. In contrast, the average escitalopram SERT occupancy levels were similar in both groups after treatment. D Shows the results of the clinical evaluation. Overt as compared to covert treatment resulted in a significantly higher percentage responders and lowered (pre-post) social anxiety as assessed with the Liebowitz Social Anxiety Scale, self-report (LSAS-SR) administered online. Error bars reflect 95% confidence intervals.
Fig. 1 Study design and main results. A Shows the whole-sample distribution of serotonin (SERT) and dopamine (DAT) transporters, expressed as non-displacable binding potentials (BPND) at the baseline PET assessment. B Illustrates the experimental manipulation; high or low response expectancies were induced by different verbal instructions. All patients were then treated under randomized conditions with escitalopram 20 mg for 9 weeks, correctly described as an effective SSRI for the overt group and incorrectly described as an active placebo in the covert group. C Shows the treatment effects on PET measures. Overt as compared to covert SSRI treatment resulted in lowered DAT availability, the significant cluster in the right putamen/pallidum is shown together with percent BPND change from pre- to posttreatment. In contrast, the average escitalopram SERT occupancy levels were similar in both groups after treatment. D Shows the results of the clinical evaluation. Overt as compared to covert treatment resulted in a significantly higher percentage responders and lowered (pre-post) social anxiety as assessed with the Liebowitz Social Anxiety Scale, self-report (LSAS-SR) administered online. Error bars reflect 95% confidence intervals.CC BY · PubMed Central
Fig. 2 Brain-behavior correlations. Significant correlations are shown between decreased dopamine transporter (DAT) availability, expressed as percent pre-post change in binding potential (BP), and symptom improvement expressed as higher scores on the Liebowitz Social Anxiety Scale self-report (LSAS-SR) before as compared to after treatment. Significant correlations were noted in the right putamen/pallidum cluster (left panel) and in the left thalamus (right panel).
Fig. 2 Brain-behavior correlations. Significant correlations are shown between decreased dopamine transporter (DAT) availability, expressed as percent pre-post change in binding potential (BP), and symptom improvement expressed as higher scores on the Liebowitz Social Anxiety Scale self-report (LSAS-SR) before as compared to after treatment. Significant correlations were noted in the right putamen/pallidum cluster (left panel) and in the left thalamus (right panel).CC BY · PubMed Central
Fig. 3 Concomitant serotonin-dopamine transporter changes with overt and covert SSRI treatment. Significant group differences in correlations between percent sertonin transporter (SERT) occupancy and change in dopamine transporter binding (DAT BP) from pre-to post-treatment were noted in the left putamen, bilateral pallidum, and right thalamus (top panel). Scatterplots are shown in the lower panel.
Fig. 3 Concomitant serotonin-dopamine transporter changes with overt and covert SSRI treatment. Significant group differences in correlations between percent sertonin transporter (SERT) occupancy and change in dopamine transporter binding (DAT BP) from pre-to post-treatment were noted in the left putamen, bilateral pallidum, and right thalamus (top panel). Scatterplots are shown in the lower panel.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 59 · Cited by 46

Metadata

Authors
Hjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., Wahlstedt, K., Jonasson, M., Lubberink, M., Antoni, G., Fredrikson, M., & Furmark, T.
Affiliations
  • Uppsala University (SE)
  • Karolinska Institutet (SE)
  • Linköping University (SE)
Corresponding author
Hjorth, Olof R.
Venue
Translational Psychiatry
Published
2021-11-03
Volume
11
Issue
1
Pages
559-559
ISSN
2158-3188 (ISSN-L)
OpenAlex
W3208201339
Cited by
46
References
59
Citations by year
2026: 10 · 2025: 5 · 2024: 9 · 2023: 11 · 2022: 11
FWCI
3.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Riksbankens Jubileumsfond
  • Vetenskapsrådet
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
Keywords
social anxiety disorder, selective serotonin reuptake inhibitors, escitalopram, placebo response, treatment expectancy, dopamine transporter, serotonin transporter, dopamine signaling, anxiolytic mechanism, putamen, globus pallidus, thalamus, treatment response
MeSH terms
Phobia, Social, Escitalopram, Dopamine, Female, Humans, Male, Serotonin, Citalopram, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. https://app.cochat.ai/papers/10.1038/s41398-021-01682-3
The paper
Hjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., Wahlstedt, K., Jonasson, M., Lubberink, M., Antoni, G., Fredrikson, M., & Furmark, T. (2021). Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. Translational Psychiatry. https://doi.org/10.1038/s41398-021-01682-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.